General Information of This Drug (ID: DMOQDN0)

Drug Name
NKX019   DMOQDN0
Drug Type
CAR-NK cell therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05020678) A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies. U.S.National Institutes of Health.